Pyrimidine MAP4K1 Inhibitors for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective and selective inhibitors for MAP4K1, a serine/threonine kinase involved in various cellular processes, which are crucial for treating diseases associated with dysfunctional protein kinase signaling such as autoimmune diseases, inflammatory diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, and asthma.
Innovation Solution
Development of novel pyrimidine phospho compounds that act as highly selective inhibitors of MAP4K1, capable of inhibiting the kinase at nanomolar concentrations, thereby modulating MAPK signal transduction pathways, particularly the JNK pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing kinase inhibitors are used, then some kinase activity is inhibited, but selectivity for MAP4K1 is insufficient leading to off-target effects
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the pyrimidine core structure. The compound features a pyrimidine ring with specific substitutions at positions 2, 4, and 6, where each position can accommodate specific functional groups (e.g., electron-withdrawing groups at position 2, aryl/alkyl groups at position 4) that collectively create high affinity and selectivity for MAP4K1 over other kinases
Solution Approach 2:
The patent employs parameter changes by systematically varying physical and chemical parameters of the inhibitor structure including molecular weight (200-500 Da), logP (2-5), hydrogen bond donors (1-3), and hydrogen bond acceptors (3-7). These parameter optimizations enable the compounds to achieve nanomolar IC50 values for MAP4K1 while maintaining selectivity against other kinases in the family
2Adaptability or versatility
If broad-spectrum kinase inhibitors are used, then multiple kinase pathways are affected, but the desired MAP4K1-specific therapeutic effect is not achieved
Solution Approach 1:
The patent applies segmentation by dividing the kinase binding site into distinct interaction regions that can be independently optimized. The pyrimidine core structure is segmented into functional zones: the N1 position for hydrogen bonding with the hinge region, the C2 position for hydrophobic interactions with the ATP binding pocket, and the N4 position for extending into the solvent-exposed region. This segmentation allows for rational design of selective inhibitors
3Reliability
If high potency inhibitors are developed, then nanomolar IC50 values are achieved, but compound complexity increases
Solution Approach 1:
The patent applies universality by designing a pyrimidine core structure that serves multiple functions simultaneously: it acts as a hydrogen bond donor/acceptor, provides hydrophobic interaction surfaces, and offers geometric constraints for selective binding. The core structure can accommodate various substituent combinations while maintaining its fundamental role as a kinase inhibitor scaffold, reducing the need for complex molecular architectures
Data Source
AI summary
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.